B.S. Johns Hopkins University, 1999Ph.D. Massachusetts Institute of Technology, 2005Post-Doc Harvard Medical School, 2005-2008
"My research combines engineering principles with molecular biology to tackle fundamental problems in cancer and infectious disease."
Kevin Janes, Professor
Kevin Janes designs and uses new experimental and computational approaches for analyzing cell signaling and transcriptional networks in cancer and infectious disease. He received his B.S. and B.A. degrees in Biomedical Engineering and Spanish at Johns Hopkins University in 1999. He was a Fulbright Scholar at La Universidad de Santiago de Compostela in Spain before attaining his Ph.D. in Bioengineering at M.I.T. in 2005 under the joint supervision of Douglas Lauffenburger and Michael Yaffe.
Dr. Janes completed a postdoctoral fellowship at Harvard Medical School in the Department of Cell Biology with Joan Brugge and began his faculty position at the University of Virginia in 2008. During that time, Dr. Janes was recognized as a Pew Scholar, a Packard Fellow, a Kavli Fellow, and a recipient of the NIH Director’s New Innovator Award. He is currently an Associate Professor in the Department of Biomedical Engineering at the University of Virginia, the Chair of the Tumor Biochemistry and Endocrinology study section at the American Cancer Society, and a member of the Board of Reviewing Editors for Science Signaling.
Awards
Elected to the College of Fellows of the American Institute for Medical and Biological Engineering2020
Research Interests
Biomedical Data Sciences
Computational Systems Biology
Quantitative Biosciences
Biomedical Data Sciences
Kevin Janes is a professor in the Department of Biomedical Engineering. He designs and uses new experimental and computational approaches for analyzing cell signaling and transcriptional networks in cancer and infectious disease.
Just a handful of universities have multiple members on the 69-person board of the journal Cell Systems, including Harvard, MIT, Princeton, Stanford, UCSF and UVA.
So-called “triple-negative” breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.
TNF-insulin crosstalk at the transcription factor GATA6 is revealed by a model that links signaling and transcriptomic data tensors. Sci Signal, 9, ra59. Chitforoushzadeh Z, Ye Z, Sheng Z, LaRue S, Fry RC, Lauffenburger DA, Janes KA. (2016)
Network architecture predisposes an enzyme to pharmacologic or genetic targeting. Cell Syst, 2, 112-21. Jensen KJ*, Moyer CB*, Janes KA. (2016)
A time- and matrix-dependent TGFBR3–JUND–KRT5 regulatory circuit in single breast epithelial cells and basal-like premalignancies. Nat Cell Biol, 16, 345-56. Wang CC, Bajikar SS, Jamal L, Atkins KA, Janes KA. (2014)
An ERK–p38 subnetwork coordinates host-cell apoptosis and necrosis during coxsackievirus B3 infection. Cell Host Microbe, 13, 67-76. Jensen KJ, Garmaroudi FS, Zhang J, Lin J, Boroomand S, Zhang M, Luo Z, Yang D, Luo H, McManus BM†, and Janes KA†. (2013)
